DK2350266T3 - Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion - Google Patents

Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion Download PDF

Info

Publication number
DK2350266T3
DK2350266T3 DK09827049.9T DK09827049T DK2350266T3 DK 2350266 T3 DK2350266 T3 DK 2350266T3 DK 09827049 T DK09827049 T DK 09827049T DK 2350266 T3 DK2350266 T3 DK 2350266T3
Authority
DK
Denmark
Prior art keywords
cells
pancreatic
stro
cell
insulin
Prior art date
Application number
DK09827049.9T
Other languages
English (en)
Inventor
Silviu Itescu
Ravi Krishnan
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of DK2350266T3 publication Critical patent/DK2350266T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37Digestive system
    • A61K35/39Pancreas; Islets of Langerhans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0676Pancreatic cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/62Insulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)

Claims (15)

1. STR0-1 + -ce I le r til anvendelse i en fremgangsmåde til forbedring af pankreatisk funktion hos et individ med behov derfor.
2. Celler til anvendelse ifølge krav 1, hvor anvendelse af cel lerne: (i) inducerer eller fremmer regeneration af pankreatiske beta-celler og/eIler Langerhansske øer; og/el ler (i i) reducerer blodsukkerniveauer og/el ler øger insulinniveauer i blod/serum; og/el I er (i i i) øger antallet af pankreatiske beta-celler og/el ler øger antallet af pankreatiske beta-celler i forhold til pankreatiske alfa-celler og/el ler reducerer antallet af pankreatiske alfa-celler og/el ler øger antallet af Langerhansske øer; og/eller (iv) øger pankreatisk og duodenal homeobox-faktor-1-(PDX-1) ekspression og/eller øger antallet af PDX-1 udtrykkende celler i en pankreas; og/eller (v) inducerer eller fremmer arte r iogenese eller angiogenese i pankreas.
3. Celler til anvendelse ifølge krav 1 eller krav 2, hvor individet lider af en pankreatisk dysfunktion forbundet med pankreas’ endokrine og/eller exokrine funktion.
4. Celler til anvendelse ifølge krav 3, hvor pankreatisk dysfunkt ionen: (a) er forbundet med eller forårsager afvigende niveauer af insulin, glucagon, somatostatin, pankreatisk polypeptid, trypsinogen, chymotrypsinogen, elastase, carboxypeptidase, pankreatisk lipase eller amylase; (b) er forbundet med eller forårsager malabsorption af nær ingsstof fer; (c) er forbundet med pancreatitis, pankreatisk insufficiens, erhvervet autoimmun deficienssyndrom, cancer, cystisk fibrose eller Zol I inger-EI I ison-syndrom; (d) resulterer i hypoglykæmi eller hyperg lykæmi, reducerede aminosyren iveauer i serum, proteinuri eller nekrolytisk migrerende erytem; eller (e) er forbundet med eller forårsager en forstyrrelse i carbohydratstofskifte.
5. Celler til anvendelse ifølge krav 4, hvor det afvigende niveau af glucagon er forårsaget af en glucagonsekreterende tumor.
6. Celler til anvendelse ifølge krav 4, hvor forstyrrelsen i carbohydratstofskifte er forårsaget af pankreas’ reducerede insulinproduktion eller af pankreas’ reducerede amylaseproduktion.
7. Celler til anvendelse ifølge krav 4 eller krav 6, hvor forstyrrelsen i carbohydratstofskifte er diabetes me 11 i t u s .
8. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ceI lerne deraf er beregnet til administration direkte ind i et individs blodbane.
9. Celler til anvendelse ifølge krav 10, hvor STRO-Γ- cellerne er beregnet til administration i n t raarter ie11.
10. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ce 11 e rne administreret til individet er STRO-1bn og/el ler udtrykker ikke-vævsspecifik alkalisk phosphatase (TNAP).
11. Celler til anvendelse ifølge et hvilket som helst af de foregående krav til behandling eller forsinkelse af progression af pankreatisk dysfunktion, hvor STRO-Γ- cellerne er beregnet til administration efter diagnosticering af lidelsen.
12. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -cel Ierne er beregnet til administration i form af en sammensætning omfattende STRO-1+-ce I le rne og et bærestof og/el ler hjælpestof og eventuelt en faktor, der inducerer eller øger differentiering af progen i to reel I e r til vaskulære celler eller sammensætningen omfatter en vævsspecifik engageret celle.
13. Celler til anvendelse ifølge et hvilket som helst af de foregående krav, hvor STRO-1 + -ce 11 e rne tidligere har væ re t dyrket in vitro.
14. Anvendelse af STRO-1 + -ce I le r i fremstillingen af et medikament til forbedring af pankreatisk funktion hos et individ med behov derfor.
15. Anvendelse ifølge krav 14, hvor medikamentet er beregnet til: (i) induktion eller fremme af regeneration af pankreatiske beta-celler og/eIler Langerhansske øer; og/eI ler (ii) reduktion af blodsukkerniveauer og/eller forøgelse af insulinniveauer i blod/serum; og/el ler (i i i) forøgelse af antallet af pankreatiske betaceller og/el ler forøgelse af antallet af pankreatiske beta-celler i forhold til pankreatiske alfa-celler og/el ler reduktion af antallet af pankreatiske alfaceller og/el ler forøgelse af antallet af Langerhansske øer; og/e 11e r (iv) forøgelse af pankreatisk og duodenal homeobox-faktor-1- (PDX-1) ekspression og/el ler forøgelse af antallet af PDX-1-udtrykkende celler i en pankreas; og/eI ler (v) induktion eller fremme af ar te r i ogenese eller angiogenese i pankreas.
DK09827049.9T 2008-11-20 2009-11-19 Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion DK2350266T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19979608P 2008-11-20 2008-11-20
PCT/AU2009/001511 WO2010057260A1 (en) 2008-11-20 2009-11-19 Method for treating or preventing a pancreatic dysfunction

Publications (1)

Publication Number Publication Date
DK2350266T3 true DK2350266T3 (da) 2015-11-02

Family

ID=42197754

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09827049.9T DK2350266T3 (da) 2008-11-20 2009-11-19 Fremgangsmåde til behandling eller forebyggelse af pankreatisk dysfunktion

Country Status (11)

Country Link
US (3) US8894972B2 (da)
EP (2) EP2350266B1 (da)
JP (6) JP5891034B2 (da)
KR (2) KR101832497B1 (da)
CN (3) CN104546912B (da)
AU (1) AU2009317874B2 (da)
CA (1) CA2744228C (da)
DK (1) DK2350266T3 (da)
ES (2) ES2550795T3 (da)
HK (2) HK1197186A1 (da)
WO (1) WO2010057260A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104546912B (zh) 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
SI2403605T1 (sl) 2009-03-05 2015-11-30 President And Fellows Of Harvard College Sestavki, ki obsegajo aP2-specifično protitelo ali njegov fragment, za uporabo pri zdravljenju diabetesa, intolerance za glukozo ali z debelostjo povzročene inzulinske rezistence
EP3366298B1 (en) * 2010-07-02 2020-08-19 Mesoblast, Inc. Treatment of graft versus host disease
AU2012255621A1 (en) 2011-05-19 2013-05-02 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
CN103841983B (zh) 2011-06-03 2018-11-02 麦瑟布莱斯特公司 治疗或预防神经性疾病的方法
US9265796B2 (en) * 2011-07-04 2016-02-23 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
CN104098682B (zh) * 2013-04-03 2018-01-02 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
CN111840329B (zh) * 2012-12-12 2024-10-15 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
CN104714021B (zh) * 2013-12-12 2016-05-25 张曼 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用
SG11201708323SA (en) 2015-04-30 2017-11-29 Harvard College Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EP3475299A4 (en) * 2016-06-27 2020-03-18 President and Fellows of Harvard College COMPOUNDS USEFUL FOR TREATING METABOLIC DISORDERS
EP3634479A4 (en) 2017-06-09 2021-04-14 President and Fellows of Harvard College PROCESS FOR IDENTIFYING COMPOUNDS USEFUL FOR TREATING DEREGULATED LIPOGENESIS, DIABETES AND OTHER RELATED DISORDERS
CN110959579A (zh) * 2019-11-14 2020-04-07 顾隽 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20040063204A1 (en) * 2002-08-14 2004-04-01 Lijun Yang Bone marrow cell differentiation
DE602004030823D1 (de) * 2003-11-04 2011-02-10 Biomaster Inc Verfahren und system zur herstellung von stammzellen aus fettgewebe
CN101506355B (zh) * 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代(memp)及其应用
KR101682046B1 (ko) * 2005-04-12 2016-12-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
GB0514785D0 (en) * 2005-07-19 2005-08-24 Innovia Films Ltd Sealed ream wrap package and films suitable for forming such packages
WO2007127408A2 (en) * 2006-04-28 2007-11-08 Tulane University Health Sciences Center Methods for treating diabetes
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
CN104546912B (zh) 2008-11-20 2019-11-08 中胚有限公司 用于治疗胰功能异常的方法
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Also Published As

Publication number Publication date
US9968640B2 (en) 2018-05-15
JP7051770B2 (ja) 2022-04-11
ES2550795T3 (es) 2015-11-12
WO2010057260A1 (en) 2010-05-27
US20110243902A1 (en) 2011-10-06
EP2350266A1 (en) 2011-08-03
US9480713B2 (en) 2016-11-01
US20170042945A1 (en) 2017-02-16
JP2023116536A (ja) 2023-08-22
HK1197186A1 (en) 2015-01-09
JP2020011972A (ja) 2020-01-23
CN104546912A (zh) 2015-04-29
US8894972B2 (en) 2014-11-25
KR20110095875A (ko) 2011-08-25
US20150064148A1 (en) 2015-03-05
JP2017214384A (ja) 2017-12-07
ES2651503T3 (es) 2018-01-26
JP2022031662A (ja) 2022-02-22
CN103800370B (zh) 2017-10-24
EP3002329A1 (en) 2016-04-06
CN102307992A (zh) 2012-01-04
AU2009317874A1 (en) 2010-05-27
CA2744228A1 (en) 2010-05-27
CN102307992B (zh) 2015-01-07
CA2744228C (en) 2018-06-19
EP2350266B1 (en) 2015-07-29
HK1223396A1 (zh) 2017-07-28
EP3002329B1 (en) 2017-08-16
JP5891034B2 (ja) 2016-03-22
JP2012509283A (ja) 2012-04-19
AU2009317874B2 (en) 2016-04-21
KR102011609B1 (ko) 2019-08-16
KR20180021230A (ko) 2018-02-28
KR101832497B1 (ko) 2018-02-26
CN104546912B (zh) 2019-11-08
EP2350266A4 (en) 2013-03-06
JP2015205894A (ja) 2015-11-19
CN103800370A (zh) 2014-05-21
JP6499016B2 (ja) 2019-04-10

Similar Documents

Publication Publication Date Title
US9968640B2 (en) Method for treating or preventing a pancreatic dysfunction
AU2018247196A1 (en) Methods for treating obesity and/or metabolic syndrome